Xiaohui He
About
Xiaohui He is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Xiaohui He has authored 128 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 67 papers in Pathology and Forensic Medicine and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaohui He's work include Lymphoma Diagnosis and Treatment (67 papers), Viral-associated cancers and disorders (37 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Xiaohui He is often cited by papers focused on Lymphoma Diagnosis and Treatment (67 papers), Viral-associated cancers and disorders (37 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Xiaohui He collaborates with scholars based in China, United States and Canada. Xiaohui He's co-authors include Shengyu Zhou, Yuankai Shi, Jianliang Yang, Liqiang Zhou, Lin Gui, Yan Qin, Changgong Zhang, Ye‐Xiong Li, Weihu Wang and Shulian Wang and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.
In The Last Decade
Xiaohui He
118 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Xiaohui He China | 20 | 995 | 823 | 323 | 320 | 316 | 128 | 1.9k | ||
| Kirtee Raparia United States | 22 | 483 0.5× | 322 0.4× | 288 0.9× | 755 2.4× | 244 0.8× | 58 | 1.7k | ||
| Henry E. Wilson United States | 21 | 1.0k 1.0× | 1.1k 1.3× | 311 1.0× | 388 1.2× | 266 0.8× | 45 | 2.2k | ||
| Megumi Ishiguro Japan | 27 | 1.4k 1.4× | 393 0.5× | 509 1.6× | 555 1.7× | 608 1.9× | 103 | 2.1k | ||
| Ho‐Jin Shin South Korea | 22 | 655 0.7× | 691 0.8× | 399 1.2× | 234 0.7× | 105 0.3× | 182 | 2.0k | ||
| Hideo Niibe Japan | 24 | 440 0.4× | 180 0.2× | 304 0.9× | 787 2.5× | 391 1.2× | 143 | 1.7k | ||
| Francesca Sanguedolce Italy | 28 | 547 0.5× | 239 0.3× | 700 2.2× | 744 2.3× | 701 2.2× | 167 | 2.3k | ||
| Laura Pala Italy | 18 | 1.3k 1.3× | 81 0.1× | 348 1.1× | 523 1.6× | 270 0.9× | 66 | 2.1k | ||
| Ngan‐Ming Tsang Taiwan | 20 | 553 0.6× | 68 0.1× | 378 1.2× | 200 0.6× | 240 0.8× | 57 | 1.3k | ||
| Chia‐Jui Yen Taiwan | 25 | 663 0.7× | 270 0.3× | 525 1.6× | 433 1.4× | 236 0.7× | 139 | 1.8k | ||
| S Hellman United States | 13 | 806 0.8× | 359 0.4× | 453 1.4× | 411 1.3× | 325 1.0× | 23 | 1.9k |
Countries citing papers authored by Xiaohui He
Since
Specialization
Citations
This map shows the geographic impact of Xiaohui He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaohui He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaohui He more than expected).
Fields of papers citing papers by Xiaohui He
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Xiaohui He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaohui He. The network helps show where Xiaohui He may publish in the future.
Co-authorship network of co-authors of Xiaohui He
This figure shows the co-authorship network connecting the top 25 collaborators of Xiaohui He. A scholar is included among the top collaborators of Xiaohui He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaohui He. Xiaohui He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Liang, Liyan, Zihao Guo, Xiaohui He, et al.. (2025). Fabry–Pérot interference-enhanced GaSe visible-blind UV photodetectors. Journal of Materials Chemistry C. 13(11). 5490–5495.
2.
Mu, Jianbing, Xuan Chen, Yuemeng Zhao, et al.. (2025). Epigenetically conferred ring-stage survival in Plasmodium falciparum against artemisinin treatment. Nature Communications. 16(1). 8037–8037.
3.
Gui, Lin, Xinrui Chen, Xiaohui He, et al.. (2024). Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 6023–6023.
4.
Qin, Yan, Xiaohui He, Xinrui Chen, et al.. (2023). Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients. European Journal Of Haematology. 111(3). 356–364.
5.
Shang, Xiaomin, Li Shen, Fei Sheng, et al.. (2022). PfAP2-EXP2, an Essential Transcription Factor for the Intraerythrocytic Development of Plasmodium falciparum. Frontiers in Cell and Developmental Biology. 9. 782293–782293.
6.
Yang, Sheng, et al.. (2021). Prognostic evaluation models for primary thyroid lymphoma, based on the SEER database and an external validation cohort. Journal of Endocrinological Investigation. 45(4). 815–824.
7.
Yang, Yunpeng, Hao Wang, Shenhong Qu, et al.. (2021). 121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC). Annals of Oncology. 32. S1430–S1430.
8.
Meng, Zhaoyou, Rui‐Hua Xu, Lexing Xie, et al.. (2021). A20/Nrdp1 interaction alters the inflammatory signaling profile by mediating K48- and K63-linked polyubiquitination of effectors MyD88 and TBK1. Journal of Biological Chemistry. 297(1). 100811–100811.
9.
Liu, Huan, Boxuan Liu, Lei Zhang, et al.. (2021). An investigation to identify tumor microenvironment-related genes of prognostic value in lung squamous cell carcinoma based on The Cancer Genome Atlas. Translational Cancer Research. 10(4). 1885–1899.
10.
Yang, Sheng, Shengyu Zhou, Jianliang Yang, et al.. (2020). Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology. 12. 3863568778–3863568778.
11.
Lv, Lingling, Haiyan Lü, Xiangqian Zhang, et al.. (2020). Transcriptome-wide identification of novel circular RNAs in soybean in response to low-phosphorus stress. PLoS ONE. 15(1). e0227243–e0227243.
12.
Jiang, Shiyu, Yan Qin, Peng Liu, et al.. (2020). Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens. Journal of Cancer. 11(6). 1516–1524.
13.
Shi, Yuankai, Ying Han, Jianliang Yang, et al.. (2019). Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chinese Journal of Cancer Research. 31(1). 152–161.
14.
Wang, Weihu, Xiaohui He, Bo Chen, et al.. (2018). Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study. International Journal of Radiation Oncology*Biology*Physics. 102(1). 61–70.
15.
Fang, Wenfeng, Yunpeng Yang, Yuxiang Ma, et al.. (2018). Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. The Lancet Oncology. 19(10). 1338–1350.
16.
Wang, Jingjing, Yanlin Wu, Mei Dong, et al.. (2015). Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-Cancer Drugs. 27(3). 245–250.
17.
Shi, Wei, Yuankai Shi, Xiaohui He, et al.. (2009). Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation. Chinese Journal of Cancer. 28(10). 1083–1087.
18.
Li, Bo, Yuankai Shi, Xiaohui He, et al.. (2008). Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. International Journal of Hematology. 87(4). 375–381.
19.
Niu, Yi, Yuankai Shi, Shengyu Zhou, et al.. (2008). Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. International Journal of Hematology. 89(1). 106–112.
20.
Zhou, Shengyu, et al.. (2005). [Clinicopathologic features of primary thyroid lymphoma].. PubMed. 24(1). 95–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kirtee Raparia Breakdown of academic impact, for papers by Henry E. Wilson Breakdown of academic impact, for papers by Megumi Ishiguro Breakdown of academic impact, for papers by Ho‐Jin Shin Breakdown of academic impact, for papers by Hideo Niibe Breakdown of academic impact, for papers by Francesca Sanguedolce Breakdown of academic impact, for papers by Laura Pala Breakdown of academic impact, for papers by Ngan‐Ming Tsang Breakdown of academic impact, for papers by Chia‐Jui Yen Breakdown of academic impact, for papers by S Hellman